Home › NDC Lookup › RxCUI directory › RxCUI 2730172

Niacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector — RxCUI 2730172

Name: Niacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector (RxCUI 2730172)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2730172 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2730172

Official nameNiacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asinsulin, aspart, human (niacinamide) 100 UNT/ML per 3 ML Pen Injector; insulin, aspart, human (niacinamide) 100 UNT/ML in 3 ML Pen Injector

FDA products mapped4

Package NDCs mapped8

Reported Medicaid activity (SDUD)30,838 prescriptions · 47 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Aspart (rDNA Origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Insulin aspart is a man-made, rapid-acting insulin that is very similar to the insulin your body makes naturally, but it works faster. After you inject it under the skin, it starts...
What exactly is insulin aspart and how is it different from regular insulin?
Generally, you should inject it within about 5 to 10 minutes before a meal so it starts working as your blood sugar begins to rise from food. The exact timing depends on which prod...
When should I inject insulin aspart — before or after eating?

📖 Read our full Insulin Aspart (rDNA Origin) Injection guide →

🕸️ Concept Web — How Niacinamide 3 ML insulin aspart, human 100 UNT/M... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Niacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector RxCUI 2730172 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Insulin aspart, human 51428 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Fiasp 1986350 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Insulin aspart, human Pen Injector 1653201 SCDF
- Insulin aspart, human Injectable Product 1157463 SCDG
- Insulin aspart, human Pen Injector [Fiasp] 1986355 SBDF
- Fiasp Injectable Product 1986353 SBDG
- Pen Injector 1649571 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Insulin aspart, human 100 UNT/ML 343211 SCDC
- Niacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector [Fiasp] 1986356 SBD
- Insulin aspart, human 100 UNT/ML [Fiasp] 1986351 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Insulin aspart, human 100 UNT/ML SCDC · 343211
Insulin aspart, human Pen Injector SCDF · 1653201
Insulin aspart, human Injectable Product SCDG · 1157463

Brand-Name Concepts

Niacinamide 3 ML insulin aspart, human 100 UNT/ML Pen Injector [Fiasp] SBD · 1986356
Insulin aspart, human 100 UNT/ML [Fiasp] SBDC · 1986351
Insulin aspart, human Pen Injector [Fiasp] SBDF · 1986355
Fiasp Injectable Product SBDG · 1986353
Fiasp BN · 1986350

📦 FDA Products & Package NDCs

4 products · 8 package NDCs

8 package NDCs map to RxCUI 2730172 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00169-3201-11	1 VIAL, GLASS in 1 CARTON (0169-3201-11) / 10 mL in 1 VIAL,...	Fiasp	Novo Nordisk	2017-10-20
00169-3201-90	1 VIAL, GLASS in 1 CARTON (0169-3201-90) / 10 mL in 1 VIAL,...	Fiasp	Novo Nordisk	2017-10-20
00169-3204-15	5 SYRINGE, PLASTIC in 1 CARTON (0169-3204-15) / 3 mL in 1 S...	Fiasp	Novo Nordisk	2017-10-20
00169-3204-97	1 SYRINGE, PLASTIC in 1 CARTON (0169-3204-97) / 3 mL in 1 S...	Fiasp	Novo Nordisk	2017-10-20
00169-3205-15	5 CARTRIDGE in 1 CARTON (0169-3205-15) / 3 mL in 1 CARTRIDG...	Fiasp	Novo Nordisk	2019-10-01
00169-3205-95	5 CARTRIDGE in 1 CARTON (0169-3205-95) / 3 mL in 1 CARTRIDG...	Fiasp	Novo Nordisk	2019-10-01
00169-3206-15	5 CARTRIDGE in 1 CARTON (0169-3206-15) / 1.6 mL in 1 CARTRI...	Fiasp	Novo Nordisk	2023-09-14
00169-3206-95	5 CARTRIDGE in 1 CARTON (0169-3206-95) / 1.6 mL in 1 CARTRI...	Fiasp	Novo Nordisk	2023-09-14

Observed labelers: Novo Nordisk (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per ml · median

$8.5633

Range $6.9217–$8.9171 · middle 50% $8.1451–$8.6595 · 4 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J1811	Fiasp for insulin pump use	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.